EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The necessity of adjuvant surgery for patients with high-risk chemorefractory or relapsed gestational choriocarcinoma with complete remission after anti-PD-1 therapy

Jiayuan Zhao iD, Dan Wang iD, Yonglan He iD, Xirun Wan iD, Jun Zhao iD, Junjun Yang iD, Yang Xiang iD

Journal of Gynecologic Oncology · 2025

DOI: 10.3802/jgo.2025.36.e130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2025. Verfasst von Jiayuan Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, …. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Choriocarcinoma, Gestational Trophoblastic Disease, Uterine Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NKRDPC, NNSFC, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Anti-programmed cell death protein 1 (PD-1) therapy has demonstrated favorable therapeutic responses in patients with chemorefractory gestational trophoblastic neoplasia. The need for combined surgery to remove resistant foci in patients treated with anti-PD-1 therapy after complete remission (CR), however, has not been investigated. We therefore compared the prognosis of patients with high-risk chemorefractory or relapsed choriocarcinoma who underwent anti-PD-1 therapy with or without surgery. METHODS: Patients with high-risk chemorefractory or relapsed choriocarcinoma who experienced CR following immunotherapy in conjunction with either surgical or non-surgical interventions were selected at Peking Union Medical College Hospital (PUMCH) between August 2018 and December 2023. Study endpoints included progression-free survival (PFS) and overall survival (OS). The results were analyzed using Mann-Whitney U tests and Kaplan-Meier analysis. RESULTS: Forty-three patients who received andi-PD-1 therapy were enrolled in this study, including 18 patients with surgery and 25 without. Most of the foci in the surgery group were solitary (77.8%). The median maximum diameters of resistant foci before immunotherapy were 2.9 (0.7-7.3) cm and 1.4 (0.8-11.2) cm in the surgery and non-surgery groups, respectively (p=0.184). The 2-year PFS rate was both 91.5% in the non-surgery group and 90.9% in the surgery group. The 2-year and 3-year OS rates were 100.0% in both groups. There was no significant difference in PFS (p=0.849) or OS (p=0.371) between the 2 groups. CONCLUSION: These results suggest that surgical resection of drug-resistant lesions may not be necessary in patients with high-risk chemorefractory or relapsed choriocarcinoma who achieve CR after anti-PD-1 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalChoriocarcinomaGestational Trophoblastic DiseaseUterine NeoplasmsImmune Checkpoint InhibitorsHumansFemalePregnancyAdultProgrammed Cell Death 1 ReceptorMiddle AgedYoung AdultRetrospective StudiesDrug Resistance, NeoplasmRemission InductionProgression-Free SurvivalPrognosis

Stichwörter der Autor:innen

ChoriocarcinomaPD-1 InhibitorSurgery

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Obstetric and Gynecologic Diseas…
  • Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Jiayuan Zhao, Dan Wang, Yonglan He, Xirun Wan, Jun Zhao, Junjun Yang, Yang Xiang

Förderung

  • NKRDPC
  • NNSFC
  • National High Level Hospital Clinical Research Funding
  • National Key Clinical Specialty Construction Project
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Zhao, J., Wang, D., He, Y., Wan, X., Zhao, J., Yang, J., & Xiang, Y. (2025). The necessity of adjuvant surgery for patients with high-risk chemorefractory or relapsed gestational choriocarcinoma with complete remission after anti-PD-1 therapy. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2025.36.e130

Vancouver

Zhao J, Wang D, He Y, Wan X, Zhao J, Yang J, et al. The necessity of adjuvant surgery for patients with high-risk chemorefractory or relapsed gestational choriocarcinoma with complete remission after anti-PD-1 therapy. Journal of Gynecologic Oncology. 2025. doi:10.3802/jgo.2025.36.e130

BibTeX
@article{Zhao2025,
  author = {Zhao, Jiayuan and Wang, Dan and He, Yonglan and Wan, Xirun and Zhao, Jun and Yang, Junjun and Xiang, Yang},
  title = {The necessity of adjuvant surgery for patients with high-risk chemorefractory or relapsed gestational choriocarcinoma with complete remission after anti-PD-1 therapy},
  journal = {Journal of Gynecologic Oncology},
  year = {2025},
  doi = {10.3802/jgo.2025.36.e130}
}
Kostenlos starten →